• Diana Taheri, Elham Roohani, Mohammad Hossein Izadpanahi, Shahaboddin Dolatkhah, Farshad Aghaaliakbari, Parnaz Daneshpajouhnejad, Mohammad Reza Gharaati, Hamid Mazdak, Shahriar Fesharakizadeh, Yasasmin Beinabadi, Reza Kazemi, and Mahtab Rahbar.
• Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
• J Res Med Sci. 2021 Jan 1; 26: 46.

BackgroundConsidering the great variations in the reported prevalence of prostate cancer across the world possibly due to different genetic and environmental backgrounds, we aimed to determine the expression pattern and the diagnostic utility of α-methylacyl coenzyme A racemase (AMACR) among Iranian patients with prostate adenocarcinoma.Materials And MethodsIn this cross-sectional study, formalin-fixed paraffin-embedded tissues of 58 patients with a definitive pathologic diagnosis of prostatic adenocarcinoma were evaluated. The expression of AMACR, intensity, and extensity of its staining was determined in selected samples by immunohistochemical technique.ResultsAMACR expression was significantly higher in neoplastic compared to normal tissue (P < 0.05). The expression of AMACR was significantly associated with the age of the patients (P = 0.04). The intensity of the staining was associated with the grade of the prostate adenocarcinoma (P = 0.04). There was no significant relationship between AMACR expression and perineural invasion. The sensitivity, specificity, positive predictive value, and negative predictive value of AMACR were 90%, 96%, 96%, and 90%, respectively.ConclusionFindings from our study indicate that AMACR could be used as a diagnostic tool for the diagnosis of prostate adenocarcinoma. However, due to false-positive staining in the mimicker of prostatic adenocarcinoma, it is recommended to use it in combination with basal cell markers.Copyright: © 2021 Journal of Research in Medical Sciences.

3 keywords...

hide…